InTrODuCTIOn
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide, with an estimated 1.8 million new cases in 2018. 1 Global patterns vary widely and are strongly linked to human development index level, reflecting the adoption of western lifestyles that accompany economic transition and elevate risk. In general, CRC incidence is rising in low-income and middle-income countries but beginning to stabilise or decline in high-income countries, especially those that have implemented screening. 2 However, accumulating evidence from studies of cancer registry data indicates that favourable overall trends are masking an increase in young-onset CRC in the USA, [3] [4] [5] [6] Australia 7 8 and Canada. 9 Although the absolute risk of CRC in adults younger than 50 years is low relative to older adults, disease trends in young age groups are a key indicator of recent changes in risk factor exposures and often foreshadow the future cancer burden. 10 In addition to country-specific analyses, there are recent reports on early-onset CRC occurrence in seven high-income countries, 11 in Europe 12 and in 11 'industrialised' countries (data through 2007). 13 However, a comprehensive examination of contemporary trends on a global scale is lacking. We analysed high-quality longterm population-based data on CRC occurrence by age at diagnosis for 43 countries covering six continents. Figure 1 Age-standardised incidence rate during 2008-2012 for colorectal cancer among adults ages 20-49 years. Bar shading indicates trend in incidence rates based on 10-year average annual per cent change; red: statistically significant increase; blue: statistically significant decrease; grey: stable or insufficient number of cases for trend analysis ( ‡). Rate for Finland unavailable.*Rate based on data during 2008-2010. †Excludes Nunavut, Quebec, and Yukon. ‡Excluded from trend analysis due to insufficient number of annual cases. ¶Rate based on data during 2008-2011.
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MeTHODS
We obtained high-quality population-based annual incidence data for colon and rectal cancer diagnosed through 2012 from the Cancer Incidence in Five Continents (CI5plus) database of the International Association of Cancer Registries and the International Agency for Research on Cancer (IARC). 14 The CI5plus database is compiled from cancer registry data worldwide using a process that ensures comparable information that meets high quality standards established by IARC. Specifically, on submission the data coding is verified, the format is standardised, and an editorial board conducts an evaluation based on three dimensions of quality: comparability, completeness and validity. (For more information about the database, see ci5. iarc. fr/ CI5-XI/ Default. aspx.) The population coverage of registries included in CI5 may be national or subnational. If a country is represented by one or more registries but without national coverage, the registries are specified. National or subnational registries with cancer incidence data going back to at least 1998 were included and multiple datasets from subnational registries within a single country were combined, resulting in a total of 43 countries examined. To take advantage of the availability of more contemporary incidence, we obtained additional data by contacting individual registries or accessing publicly available data online. We acquired data through 2015 from Australia ( www. aihw. gov. au/); through 2016 from Finland (personal communication), New Zealand (personal communication) and the USA ( seer. cancer. gov/ data/); and through 2017 from Norway (personal communication) and Sweden ( sdb. socialstyrelsen. se/ if_ can/ val. aspx). Seven countries had fewer than 10 CRC cases among ages 20-49 years in any single diagnosis year and were excluded from trend analysis.
Incidence was stratified by age at diagnosis, categorised as 20-49 years ('early-onset') or 50 years or older ('older adults'). Cancer subsite was categorised according to the International Classification of Diseases, 10th revision as colon (code C18) or rectum (code C19-C20). Given that trends in CRC incidence are quite similar in men and women overall 2 and for earlyonset disease, 6 15 16 the two sexes were combined to improve stability. Primary outcome measures were average annual incidence rates during diagnosis years 2008-2012 (42 countries; data unavailable for Finland) and time-weighted average annual per cent change (AAPC) in incidence rates during the last 10 years of available data (36 countries) based on joinpoint regression analysis. This method fits joined straight lines (joinpoints) to observed annual age-standardised rates on a logarithmic scale. 17 The maximum number of joinpoints is determined by the number of years available for each country/registry and was limited to four for countries with ≥24 data years. Trends are described as 'increasing' or 'decreasing' if the AAPC is statistically significantly different from zero (p<0.05) and 'stable' otherwise. All rates are expressed per 100 000 population and age-standardised to the 1960 Segi world standard population (as modified by Doll and Cook). 18 In a sensitivity analysis, we assessed the extent to which the inclusion of appendiceal cancer (C18.1) in the CI5plus grouping for colon cancer influenced our results by calculating rates and trends exclusive of appendix for three countries for which these data were available (USA, New Zealand and Canada).
reSulTS
CrC incidence during 2008-2012
Among 42 countries with high-quality population-based cancer registry data, cross-sectional age-standardised CRC incidence rates in ages 20-49 years during 2008-2012 were lowest in India (Chennai; 3.5 per 100 000 (95% CI 3.2 to 3.9)); Uganda (3.8, 95% CI 3.0 to 4.6); and Chile (3.8, 95% CI 2.5 to 5.1) and highest in Korea (12.9, 95% CI 12.6 to 13.3); Australia (11.2, 95% CI 10.9 to 11.5); the USA (10.0, 95% CI 9.8 to 10.3); and Slovakia (10.0, 95% CI 9.3 to 10.7; figure 1; online supplementary table 1). The pattern in older adults was quite similar, with rates ranging from 27.5 (95% CI 25.9 to 29.1) in India to 192.5 (95% CI 188.6 to 196.3) in Slovakia (online supplementary table 2). Among young adults, incidence was generally higher for tumours developing in the colon than in the rectum, with a more than twofold difference in rates in Iceland, Italy and Cyprus (online supplementary tables 3 and 4). Exceptions were in Slovenia, where rates were similar, and Korea, India and China, where rates were slightly higher for rectal cancer. In contrast, incidence rates in older adults were a minimum of 7% higher for colon cancer than for rectal cancer (India, 14.2 per 100 000 vs 13.3) and commonly twofold higher, particularly in high incidence countries (online supplementary tables 5 and 6). 
CrC incidence trends
Among 36 countries with a sufficient number of annual cases, CRC incidence in adults <50 during the past 10 years was stable in 14 countries and decreased in three-Austria, Italy and Lithuania-all by about 1% annually (online supplementary table 1). Incidence in adults 50 and older likewise declined in Austria and Italy, as well as in nine additional countries (online supplementary table 2). The increasing CRC trend in adults <50 in the remaining 19 countries was unique to that age group in nine countries ( figure 2A ). Among these nine countries, rates in older adults declined by 1%-2.4% per year in Germany, Canada, New Zealand, Australia, and USA, and were stable in UK, Sweden, Denmark, and Slovenia. Where data were available prior to 1990, the uptick in early-onset CRC began during 1992-1996 and was preceded by declining rates except in Slovenia, where there was a continuous increase of 0.8% per year from 1983 to 2012 (figure 3; online supplementary table 1).
Early-onset CRC incidence increased most rapidly in Korea (AAPC, 4.2 (95% CI 3.4 to 5.0)), where rates rose at a similar pace among adults 50 and older (figure 2B). Incidence increased in both younger and older age groups in about one-quarter of countries examined; among these, the magnitude of the AAPC for young adults was notably larger than that for older adults in Cyprus, Netherlands and Norway. In Norway, for example, the AAPC was 1.9 (95% CI 1.4 to 2.5) among ages 20-49 versus 0.5 (95% CI 0.3 to 0.7) among ages 50 and older (figure 2B; online supplementary tables 1 and 2). In the Netherlands, the respective AAPCs were 2.0 (95% CI 1.6 to 2.4) versus 1.1 (95% CI 0.7 to 1.6), and the most recent linear (joinpoint) segment (2007-2012) was stable in older adults. Incidence in young adults began to increase in 1998 in Netherlands and 1996 in Norway according to joinpoint analysis, consistent with the timing of the trend in other high-income countries.
Subsite-specific incidence trends
Subsite-specific incidence trends varied with no clear pattern. For example, declines in early-onset CRC were confined to colon cancer in Italy and Lithuania, but to rectal cancer in Austria (online supplementary tables 3-4). In countries with increasing rates exclusively for early-onset disease, AAPCs were comparable for colon and rectal tumours in the USA, Sweden and Denmark; larger for, or confined to, colon tumours in Australia, New Zealand, Germany and UK; and larger for rectal tumours in Canada and Slovenia. Notably, rectal cancer incidence in the Netherlands increased among adults <50 years (AAPC, 1.9 (95% CI 1.4 to 2.5)) but not among older adults (AAPC, −0.1 (95% CI −0.8 to 0.7)). Importantly, the interpretation of these subsite-specific differences is limited by the inclusion of appendiceal malignancies (C18.1) within the grouping for colon cancer (C18) in CI5 data. The AAPC for appendiceal cancer incidence in the USA during 2007-2016 was 15.5 (95% CI 11.5 to 19.7) in ages 20-49 years. 19 We evaluated the extent to which the inclusion of appendiceal malignancies influenced our results by calculating AAPCs for CRC and colon cancer in the absence of appendiceal cancer for three countries (USA, New Zealand and Canada) for which these data were available. In the USA, the AAPC during 2007-2016 in ages 20-49 years excluding appendix was 1.7 (95% CI 1.5 to 2.0) for CRC (vs 2.2 (95% CI 1.9 to 2.5) including appendix) and 1.3 (95% CI 1.0 to 1.7) for copyright. on September 10, 2019 at Emory Univ Health Science Library. Protected by http://gut.bmj.com/ Gut: first published as 10.1136/gutjnl-2019-319511 on 5 September 2019. Downloaded from colon cancer (vs 2.1 (95% CI 1.7 to 2.6) including appendix) (online supplementary table 7). Thus, the AAPC for colon cancer (excluding appendix) is substantially smaller than that for rectal cancer (2.1, 95% CI 1.7 to 2.5) whereas it previously appeared identical. Results were similar for New Zealand and Canada.
DISCuSSIOn
We found that the geographic variation in CRC incidence among adults ages 20-49 mirrors that in older adults, with a threefold difference between the highest (12.9 per 100 000 in Korea) and lowest (3.5 per 100 000 in India) rates. In contrast, age-specific temporal trends were variable, with a decline limited to three countries (Austria, Italy and Lithuania) for young-onset CRC versus 11 for older adults. Conversely, increasing incidence was unique to young adults in nine high-income countries (Australia, Canada, Denmark, Germany, New Zealand, Slovenia, Sweden, UK and USA) spanning three continents, often against a backdrop of rapidly declining rates in older adults. Similarly, increasing trends in Cyprus, Netherlands and Norway were twice as steep in young adults as in older adults. Our findings are consistent with previous, mostly country-level studies of age-related differences in temporal trends of CRC. 5 7-9 11 The most rapid increases in early-onset CRC occurred in countries where rates are already highest, such as Korea, which had the same pattern for older adults. Reasons for the high and escalating burden in Korea are unclear, but may be related to the rapid dietary transition that took place in the wake of remarkable economic growth following the Korean war. 20 Changes in the food supply were also initiated by the importation of wheat from the USA in response to food shortages in the late 1960s, which prompted the production of many wheat-derived processed foods during the 1970s. Shortly thereafter was the introduction of fast-food restaurants especially popular among youth. The obesity epidemic may also be a factor, given that East Asia has experienced among the largest relative increases in body mass index (BMI) worldwide among both adults and children. 21 Asians have disproportionately high levels of visceral adiposity compared with Caucasians, 22 23 which may more strongly influence CRC risk than BMI or waist circumference. 24 25 Another potential contributor is the high prevalence of early-life antibiotic use, which has been associated with increased risk of colorectal adenoma, especially in the rectum. 26 A recent study found that among six high-income countries, South Korea had the highest rate of paediatric antibiotic consumption, sevenfold higher than that in Norway, which had the lowest rate. 27 The adenoma detection rate among Korean individuals in their 40s has been reported at almost 30%, 28 three times higher than that in Australians. 29 Early-onset CRC also increased rapidly in countries where risk in older adults is declining at a similar pace, such as New Zealand, Australia, Canada and the USA. Reductions in CRC incidence among older adults in some countries are partly attributed to changing patterns in risk factors, such as reductions in smoking and widespread use of anti-inflammatory drugs. 2 30 Likewise, rising incidence confined to young age groups signals changes in early life exposures that adversely influence CRC risk, particularly given the strong birth cohort effect apparent in the trend. 5 9 11 Notably, eight of the nine countries with a unique rise in early-onset CRC had declining rates prior to the uptick beginning in the mid-1990s. Reductions in the prevalence of protective factors, such as physical activity (for colon cancer) and sufficient intake of dietary fibre, dairy, and fruits and vegetables, may play a role, as well as increased prevalence of obesity, smoking, red and/or process meat consumption, and/or excess alcohol consumption. 31 Obesity was recently found to be associated with a 20% excess risk of early-onset CRC, 32 and prevalence has risen most rapidly in young adults 33 and in English-speaking high-income countries, 34 consistent with early-onset CRC patterns. However, increases in BMI are quite similar across Europe, despite varying CRC trends. For example, BMI increased from 24 kg/m 2 in 1975 to 27 in 2014 in men in Germany, where early-onset CRC increased, as well as in Austria, Croatia, Israel and Italy, where it did not. 34 BMI increases in women were smaller but also comparable. In addition, there are puzzling variations in the CRC trend by subsite, 5 11 as well as by race/ethnicity and state within the USA, 35 36 that suggest a role for risk factors beyond obesity. For example, obesity and a sedentary lifestyle are more strongly associated with colon tumours, [37] [38] [39] [40] yet rectal tumours appear to be driving the increase based on our findings herein and those of other studies. 5 9 11 35 If this is true, the rectal epithelium may be more exposed and/or susceptible to the carcinogenic mechanisms causing the increase in disease.
CRC risk is intrinsically linked to diet and its influence on gut immune response and inflammation. 41 The global food supply has changed substantially in recent decades 42 and evolving research is exploring the carcinogenic potential of relatively new food components. For example, associations have been uncovered between CRC and moderate consumption of sugar-sweetened beverages, 43 as well as high fructose corn syrup specifically in animal studies, 44 both in the absence of obesity and metabolic syndrome. An inflammatory diet, characterised by high consumption of processed foods and high-glycaemic load carbohydrates, creates an environment conducive to colonic proliferation 45 and appears to increase CRC risk. 46 What remains uncertain is how these dietary elements might influence early-life gut health. Importantly, the association between CRC and currently established risk factors is based almost entirely on disease occurrence in older aged cohorts. 47 CRC screening programmes have mostly emerged over the past two decades and likely contributed to the declines in incidence among older adults in 11 countries. Of the 36 countries in our trend analysis, only four (Costa Rica, Cyprus, India and Philippines) lack a screening programme according to a recent global overview. 48 In most countries, screening for CRC (generally with a stool test) is recommended to begin between the ages of 50 and 60 years. Exceptions are Italy, where screening begins at age 44 years, and China, Japan and Austria, where it begins at age 40. Notably, two (Austria and Italy) of the three countries where early-onset CRC declined have screened individuals beginning in their fourth decade since the early 1980s. 48 Moreover, the decreasing trend among young adults in both Austria and Italy was confined to ages 40-49 years, with rates in ages 20-39 years increasing by 3% per year in Austria (data not shown). Although some of the rapid increases in early-onset CRC are reminiscent of the Korean thyroid cancer 'epidemic' that resulted from widespread ultrasound screening, 49 overdetection of early-onset CRC is unlikely because screening before age 50 is rare in most countries, and mortality rates have also begun to rise. 12 50 After an extensive evidence review, the American Cancer Society recently lowered the recommended age to begin screening from 50 to 45 because disease risk in individuals under 50 has shifted substantially 51 and Cancer Intervention and Surveillance Modeling Network modelling studies found a greater benefit to burden ratio for initiation at age 45 compared with 50. 52 
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the process of conducting an evidence review and expected to issue an updated recommendation by 2020-2021.
Our study is the first to provide a comprehensive global assessment of contemporary trends in early-onset CRC based on high-quality population-based cancer incidence information. However, the interpretation of subsite-specific differences in CI5 data is limited by the inclusion of appendiceal malignancies within the grouping for colon cancer. Accumulating evidence suggests that these tumours differ from those that develop in the colon in their biology and other characteristics. 55 Inclusion of appendix attenuates comparisons of the burden for colon versus rectal cancer. Additionally, although appendiceal cancer accounts for only about 10% of cases in ages <50 years (data for USA, New Zealand and Canada), incidence rates are rising rapidly in high-income countries 56 57 due to changes in classification and improved detection. This likely hindered our ability to detect the steeper rise for rectal than for colon cancer that has been reported by numerous studies of early-onset CRC trends excluding appendix, 5 9 11 but less often by those including appendix. 12 Similarly, results from our sensitivity analyses that excluded appendix found larger increases for rectal than for colon tumours in each of the three countries with these data available. Incidence trends may also be influenced by temporal improvements in the quality of data, case capture, and specificity of coding. Other study limitations include incomplete population coverage for long-term incidence data in many countries; lack of more contemporary data (eg, since 2012) for most countries; and the absence of high-quality cancer registry data for the majority of low-income and middle-income countries.
In summary, CRC incidence rates uniquely increased in young adults over the past two decades in nine high-income countries spanning three continents, often in sharp contrast to rapid declines in older adults. These patterns potentially signal changes in early-age exposures conducive to large bowel carcinogenesis and highlight an urgent need for research to explore the potentially unique aetiology of young-onset CRC. Beyond awaiting scientific discovery, clinicians have an opportunity to help mitigate premature morbidity and mortality from CRC with active documentation of familial cancer history; timely follow-up of symptoms, regardless of patient age; and screening when appropriate.
